The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.

Abstract

OBJECTIVE To investigate the efficacy, safety, and pharmacokinetics of two dosing schedules of BI 2536, a novel polo-like kinase-1 inhibitor, in patients with relapsed stage IIIB/IV non-small cell lung cancer. METHODS Ninety-five patients were randomized to intravenous BI 2536 on day 1 (200 mg) or days 1 to 3 (50 or 60 mg) of a 21-day treatment course. BI… (More)
DOI: 10.1097/JTO.0b013e3181d95dd4

Topics

Cite this paper

@article{Sebastian2010TheEA, title={The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.}, author={Martin Sebastian and Martin Reck and Cornelius Florian Waller and Cornelius Kortsik and Norbert Frickhofen and Martin Schuler and Holger Fritsch and Birgit Gaschler-Markefski and Gertraud Hanft and Gerd Munzert and Joachim von Pawel}, journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer}, year={2010}, volume={5 7}, pages={1060-7} }